FD 501

Drug Profile

FD 501

Latest Information Update: 30 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SSP Co
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 04 Aug 1998 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
  • 13 May 1996 Preclinical development for Bacterial infections in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top